Journal of Drugs in Dermatology最新文献

{"title":"Risankizumab Associated With Lower Incident Depression and Sleep Disorders in Psoriasis: A TriNetX Study.","authors":"Victoria Garfinkel, Hermon Feron, Kaveh Nezafati","doi":"10.36849/JDD.9973","DOIUrl":"https://doi.org/10.36849/JDD.9973","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"762-763"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Comorbidities Associated With Psoriasis Diagnosis in the MEPS National Cohort.","authors":"Robert Adler, Isha Gandhi, Tristi Edwards, Katerina Svigos, Jeannette Jakus","doi":"10.36849/JDD.9724","DOIUrl":"https://doi.org/10.36849/JDD.9724","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"760-761"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Speed of Response in Biologic Treatments for Moderate-to-Severe Plaque Psoriasis: Bayesian Network Meta-Analysis.","authors":"M Zaid Shami, Shivkar Amara, Stephanie V Shimon, Isabella Kest, Rahib K Islam, Luciano Moffatt, Mark Lebwohl","doi":"10.36849/JDD.10111","DOIUrl":"https://doi.org/10.36849/JDD.10111","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic inflammatory condition affecting approximately 3% of adults in the United States (US). While biologic therapies have transformed treatment for psoriasis, the speed and efficacy of response vary among biologics. This network meta-analysis (NMA) evaluates the efficacy and speed of response of interleukin (IL)-17 and IL-23, and tumor necrosis factor-alpha (TNF-alpha) inhibitors during the first 8 weeks of treating moderate-to-severe plaque psoriasis.</p><p><strong>Methods: </strong>This Bayesian NMA used data from 53 phase 2b and 3 randomized controlled trials (RCTs). Efficacy was measured by Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 (&ge;75%, &ge;90%, and 100% reduction in PASI score) at weeks 4 and 8. Absolute differences (absolute response minus placebo; AD) were calculated using a random-effects model.</p><p><strong>Results: </strong>IL-17 inhibitors, specifically brodalumab, bimekizumab, and ixekizumab, had the highest AD in PASI 75, PASI 90, and PASI 100 at week 4 and week 8.</p><p><strong>Discussion/conclusion: </strong>IL-17 inhibitors, specifically bimekizumab, brodalumab, and ixekizumab, had a higher percentage of patients (measured as absolute difference in this study), achieving PASI 75, PASI 90, and PASI 100 at week 4 and week 8. However, there was no significant difference in absolute difference for the same endpoints and time points for patients treated with brodalumab, bimekizumab, and ixekizumab. IL-23 inhibitors, while effective, exhibited a slower onset; TNF-alpha inhibitors, except infliximab, generally showed slower responses. Indirect comparisons and differences in study design and populations may limit the generalizability of the results. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"686-694"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Accuracy of ChatGPT in Identifying Contact Allergens in Commonly Prescribed Topical Therapies for Psoriasis.","authors":"Sabrina Fong, Alexandra Flamm, John G Zampella","doi":"10.36849/JDD.10000","DOIUrl":"https://doi.org/10.36849/JDD.10000","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"758-759"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study.","authors":"Alexandra Nigro, Lara Shqair, Isabel C Silva, Saakshi Khattri","doi":"10.36849/JDD.9791","DOIUrl":"https://doi.org/10.36849/JDD.9791","url":null,"abstract":"<p><strong>Background: </strong>Acne is a common cutaneous adverse event associated with Janus kinase (JAK) inhibitors, with incidence varying across agents. Substantial increase in JAK inhibitor use has been accompanied by presentation of acne as a side effect, yet data describing its clinical features remain limited. This paper aims to characterize the demographic features, timing, and clinical presentation of acne associated with oral JAK inhibitor therapy across multiple agents.</p><p><strong>Methods: </strong>We conducted a retrospective chart review of patients treated at Mount Sinai Dermatology who were prescribed oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib, abrocitinib, or ritlecitinib) and had a documented diagnosis of acne. Data collected included patient demographics, JAK inhibitor type, treatment indication and duration, and acne characteristics, including distribution and time to onset. Descriptive statistics were reported as n (%), mean &plusmn; SD, or median (IQR).</p><p><strong>Results: </strong>Fifty-seven (57) patients developed acne while receiving JAK inhibitors. The cohort was predominantly female (70%) and White (53%), with a mean age of 34.2 &plusmn; 13.2 years. Upadacitinib was the most frequently implicated agent (72%), followed by tofacitinib (11%), baricitinib (7%), abrocitinib (5%), and ritlecitinib (5%). For those with documented treatment initiation dates, the median time from JAK inhibitor initiation to acne diagnosis was 91 days (IQR, 33.5&ndash;198).</p><p><strong>Conclusion: </strong>Acne is an increasingly observed dermatologic adverse event in patients treated with JAK inhibitors. This study further characterizes the timing and clinical presentation of JAK-induced acne and may enhance patient counseling, clinical monitoring, and management strategies as JAK inhibitor use continues to expand. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"732-735"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molluscum Contagiosum in the Pediatric Population: Expert Consensus Guidance on Prevention and Treatment.","authors":"Nanette B Silverberg, Latanya Benjamin, Mercedes E Gonzalez, Adelaide A Hebert, Pearl C Kwong, Peter Lio, Anthony Mancini, Vanja Adzovic, Anneke Andriessen, Lawrence A Schachner","doi":"10.36849/JDD.10025","DOIUrl":"10.36849/JDD.10025","url":null,"abstract":"<p><strong>Background: </strong>Molluscum contagiosum (MC), caused by the molluscum contagiosum virus, is a common viral skin infection in children. MC may persist for months to years and can substantially impair the quality of life for affected children and their families through discomfort, pruritus, cosmetic concerns, social stigma, and household transmission. Newer US Food and Drug Administration (FDA)-approved therapies have demonstrated patient-acceptable clearance rates, providing clinicians with additional options to treat pediatric MC. The paper summarized literature on MC in childhood and provided evidence-based guidance to help clinicians manage pediatric MC.</p><p><strong>Methods: </strong>A panel of dermatologists developed a consensus paper to address the challenges of treating pediatric MC. The modified Delphi process comprised a two-pronged literature review, development of evidence-supported statements, physician review and modification, and a face-to-face panel meeting to discuss the systematic literature search results and draw on clinical experience and opinion to create six consensus statements, followed by voting.</p><p><strong>Results: </strong>Consensus was achieved for 6 statements. Self-limiting, prolonged infection is common, particularly in children with impaired skin barrier conditions and immune deficiencies. Families may seek treatment to reduce patient discomfort from inflammatory symptoms, limit transmission, and reduce disease burden. Physicians should focus on patient and family quality of life through education and shared decision-making. Berdazimer gel 10.3% and cantharidin 0.7% are FDA-approved therapies that achieve meaningful lesion clearance (&gt;50%) within 6 weeks to 3 months.</p><p><strong>Conclusions: </strong>The use of FDA-approved therapies with clinically meaningful clearance rates, combined with supportive management, provides an opportunity to improve outcomes and quality of life for children with MC. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"717-725"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 Receptor Agonist Use for Diabetes Mellitus is Associated With Reduced Psoriasis Disease Severity.","authors":"Toan N Vu, Sahithi Talasila, Umer Nadir, George M Jeha, Stanislav N Tolkachjov","doi":"10.36849/JDD.10057","DOIUrl":"https://doi.org/10.36849/JDD.10057","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"753-755"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of Rosacea With Tirzepatide: A Case Report.","authors":"Maheen N Mirza, Madiha Khan-Walton, David Esguerra","doi":"10.36849/JDD.10058","DOIUrl":"https://doi.org/10.36849/JDD.10058","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"749-750"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics for Pediatric Hidradenitis Suppurativa: An Update on the Evolving Therapeutic Landscape.","authors":"Nikkia Zarabian, Mina Farah, Anastasia Chajecki, Olive Osuoji, Adam Friedman","doi":"10.36849/JDD.0826","DOIUrl":"https://doi.org/10.36849/JDD.0826","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"765-766"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INDIVIDUAL ARTICLE: Generalized Pustular Psoriasis: A Contemporary Review of Diagnosis, Pathophysiology, and IL-36 Pathway-Directed Management.","authors":"Naiem T Issa, Mark Lebwohl, Raj Chovatiya, Leon Kircik","doi":"10.36849/JDD.63121","DOIUrl":"https://doi.org/10.36849/JDD.63121","url":null,"abstract":"<p><strong>Observations: </strong>Emerging epidemiologic, clinical, and real-world data establish GPP as a distinct disease entity associated with high rates of hospitalization, multisystem involvement, and increased mortality. Accurate diagnosis requires recognition of characteristic cutaneous findings together with laboratory and clinical evidence of systemic involvement, and exclusion of key mimickers such as acute generalized exanthematous pustulosis, as well as recognition of patient-reported systemic symptoms such as fever, malaise, and joint pain. Advances in pathophysiologic understanding have identified dysregulated innate immune signaling centered on the interleukin-36 (IL-36) pathway as the primary driver of neutrophilic inflammation and pustule formation. Randomized clinical trials, real-world evidence, and meta-analyses consistently demonstrate that IL-36 receptor blockade achieves rapid and reliable control of acute GPP flares and provides a rational strategy for flare prevention. In contrast, off-label biologic therapies targeting IL-17, IL-23, or tumor necrosis factor-&alpha; show more variable and often delayed efficacy, particularly for acute disease control.</p><p><strong>Conclusions and relevance: </strong>Contemporary evidence supports a paradigm shift toward disease-specific, pathway-directed management of GPP, with IL-36 pathway inhibition positioned as the cornerstone of modern therapy. &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"25 8","pages":"63121"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}